{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:16:05Z","timestamp":1791353765796,"version":"4.3.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,6,12]],"date-time":"2015-06-12T00:00:00Z","timestamp":1434067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,6,12]],"date-time":"2015-06-12T00:00:00Z","timestamp":1434067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1038\/leu.2015.135","type":"journal-article","created":{"date-parts":[[2015,6,12]],"date-time":"2015-06-12T06:52:25Z","timestamp":1434091945000},"page":"255-258","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome"],"prefix":"10.1038","volume":"30","author":[{"given":"N","family":"Landberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Askmyr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"\u00c5gerstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Lassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Rissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Hjorth-Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Mustjoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"J\u00e4r\u00e5s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Fioretos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,6,12]]},"reference":[{"key":"BFleu2015135_CR1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren R . Mechanisms of BCR\u2013ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5: 172\u2013183.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2015135_CR2","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1038\/leu.2010.159","volume":"24","author":"I Sloma","year":"2010","unstructured":"Sloma I, Jiang X, Eaves AC, Eaves CJ . Insights into the stem cells of chronic myeloid leukemia. Leukemia 2010; 24: 1823\u20131833.","journal-title":"Leukemia"},{"key":"BFleu2015135_CR3","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","volume":"105","author":"M Deininger","year":"2005","unstructured":"Deininger M, Buchdunger E, Druker BJ . The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005; 105: 2640\u20132653.","journal-title":"Blood"},{"key":"BFleu2015135_CR4","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. 2013 Blood 2013; 122: 872\u2013884.","journal-title":"Blood"},{"key":"BFleu2015135_CR5","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1158\/1078-0432.CCR-13-1988","volume":"20","author":"FX Mahon","year":"2014","unstructured":"Mahon FX, Etienne G . Deep molecular response in chronic myeloid leukemia: the new goal of therapy? Clin Cancer Res 2014; 20: 310\u2013322.","journal-title":"Clin Cancer Res"},{"key":"BFleu2015135_CR6","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1038\/leu.2013.19","volume":"27","author":"S Mustjoki","year":"2013","unstructured":"Mustjoki S, Richter J, Barbany G, Ehrencrona H, Fioretos T, Gedde-Dahl T et al. Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients. Leukemia 2013; 27: 1520\u20131526.","journal-title":"Leukemia"},{"key":"BFleu2015135_CR7","doi-asserted-by":"publisher","first-page":"16280","DOI":"10.1073\/pnas.1004408107","volume":"107","author":"M Jaras","year":"2010","unstructured":"Jaras M, Johnels P, Hansen N, Agerstam H, Tsapogas P, Rissler M et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci USA 2010; 107: 16280\u201316285.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2015135_CR8","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1182\/blood-2013-10-536078","volume":"123","author":"H Herrmann","year":"2014","unstructured":"Herrmann H, Sadovnik I, Cerny-Reiterer S, Rulicke T, Stefanzl G, Willmann M et al. Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia. Blood 2014; 123: 3951\u20133962.","journal-title":"Blood"},{"key":"BFleu2015135_CR9","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1182\/blood-2012-12-475194","volume":"123","author":"E Nievergall","year":"2014","unstructured":"Nievergall E, Ramshaw HS, Yong ASM, Biondo M, Busfield SJ, Vairo G et al. Monoclonal antibody targeting of IL-3 receptor with CSL362 effectively depletes CML progenitor and stem cells. Blood 2014; 123: 1218\u20131228.","journal-title":"Blood"},{"key":"BFleu2015135_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/10428190500272507","volume":"47","author":"S Florian","year":"2006","unstructured":"Florian S, Sonneck K, Hauswirth AW, Krauth M-T, Schernthaner G-H, Sperr WR et al. Detection of molecular targets on the surface of CD34+\/CD38\u2013 stem cells in various myeloid malignancies. Leuk Lymphoma 2006; 47: 207\u2013222.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2015135_CR11","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1158\/0008-5472.CAN-13-2797","volume":"74","author":"A Levescot","year":"2014","unstructured":"Levescot A, Flamant S, Basbous S, Jacomet F, Feraud O, Anne Bourgeois E et al. BCR-ABL-induced deregulation of the IL-33\/ST2 pathway in CD34(+) progenitors from chronic myeloid leukemia patients. Cancer Res 2014; 74: 2669\u20132676.","journal-title":"Cancer Res"},{"key":"BFleu2015135_CR12","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/ejh.12423","volume":"94","author":"H Hjorth-Hansen","year":"2014","unstructured":"Hjorth-Hansen H, Stenke L, S\u00f6derlund S, Dreimane A, Ehrencrona H, Gedde-Dahl T et al. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). Eur J Haematol 2014; 94: 243\u2013250.","journal-title":"Eur J Haematol"},{"key":"BFleu2015135_CR13","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","volume":"30","author":"D Marin","year":"2012","unstructured":"Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012; 30: 232\u2013238.","journal-title":"J Clin Oncol"},{"key":"BFleu2015135_CR14","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/leu.2012.85","volume":"26","author":"B Hanfstein","year":"2012","unstructured":"Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012; 26: 2096\u20132102.","journal-title":"Leukemia"},{"key":"BFleu2015135_CR15","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/leu.2011.347","volume":"26","author":"JJ Janssen","year":"2011","unstructured":"Janssen JJ, Deenik W, Smolders KG, van Kuijk BJ, Pouwels W, Kelder A et al. Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib. Leukemia 2011; 26: 977\u2013984.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2015135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015135","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2015135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:05:23Z","timestamp":1648742723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2015135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,12]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["BFleu2015135"],"URL":"https:\/\/doi.org\/10.1038\/leu.2015.135","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,12]]},"assertion":[{"value":"12 June 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MJ and TF are cofounders and have equity ownership in Cantargia AB (Ideon Medical Village, Lund, Sweden) formed with Lund University Bioscience AB. JR has stock options in Cantargia AB and has received honoraria from Novartis and Bristol-Myers Squibb. SM has received research funding from Novartis, Bristol-Myers and Squibb and Pfizer and honoraria from Novartis and Bristol-Myers and Squibb. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}